Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer : results from the Spanish early access program
Bernabé, Reyes (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia))
Garrido, Pilar (Hospital Universitario Ramón y Cajal (Madrid))
García-Campelo, Rosario (Complejo Hospitalario Universitario de A Coruña)
Palmero, Ramón (Hospital Universitari de Bellvitge)
Artal, Ángel (Hospital Universitario Miguel Servet (Saragossa))
Bayona, Cristina (Hospital General Yagüe (Burgos))
Rodríguez-Abreu, Delvys (Hospital Universitario Insular de Gran Canaria)
López-Brea, Marta (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria))
Paredes, Alfredo (Hospital de Donostia (Sant Sebastià, País Basc))
Vicente, David (Hospital Universitario Virgen Macarena (Sevilla, Andalusia))
Sánchez Torres, José Miguel (Hospital Universitario de la Princesa (Madrid))
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau)
Diz Taín, Pilar (Complejo Asistencial Universitario de León)
Gordo, Rocío (Roche Farma. S.A.)
Coca, Margarita (Roche Farma. S.A.)
de Castro, Javier (Hospital Universitario La Paz (Madrid))

Date:	2022
Abstract:	This retrospective observational study analyzed the clinical characteristics, treatment patterns and outcomes of 120 patients with advanced ALK-positive nonsmall-cell lung cancer (ALK+ NSCLC) according to data collected between November 2019 and October 2020 in 38 Spanish hospitals. Patients had progressed after 1-5 prior treatment lines (which included crizotinib in any prior line) and received subsequent therapy with alectinib in a local expanded access program. Median age was 58. 7 years, 50% of patients were female, 64. 1% had ECOG PS of 0-1, 85% presented stage IV, 95% had adenocarcinoma histology and 20. 8% had brain metastases. After a median 9. 6 months of alectinib treatment, objective response rate (ORR) was 54. 5%, disease control rate (DCR) was 80%, median progression-free survival (PFS) was 9. 4 months and median overall survival (OS) was 24. 1 months. Patients with brain metastases achieved an intracranial DCR of 71. 4%. Adverse events (AEs) were reported in 35. 8% of patients (14. 2% of AEs were grade ≥3). Over 40% of patients received some treatment after alectinib, most frequently lorlatinib (65. 2%) and brigatinib (32. 6%). This study provides information on real-world treatment patterns and confirms the tolerability and prolonged PFS and OS observed with alectinib in clinical trials, in unselected pretreated patients with advanced ALK+ NSCLC.
Note:	Altres ajuts: Roche Farma, S.A.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	ALK-positive NSCLC ; ALK inhibitor ; Crizotinib ; Alectinib ; Unselected patient
Published in:	Oncotarget, Vol. 13 Núm. 1 (2022) , p. 812-827, ISSN 1949-2553

DOI: 10.18632/oncotarget.28244
PMID: 35720977

16 p, 1.6 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles